SUNNYVALE, Calif., June 10, 2025 /PRNewswire/ -- In a major milestone for heart failure treatment, the first commercial patients in the U.S. have been successfully implanted with the FDA-approved ...
- Initial clinical data expected in the second half of 2025 from this first-of-its-kind trial to administer a targeted radiotherapy conditioning agent with a commercial CAR-T therapy - Iomab-ACT ...
YUTREPIA now available to be prescribed to patients via specialty pharmacies FDA approved YUTREPIA on May 23, 2025 Court denies United Therapeutics’ request for preliminary injunction and a temporary ...
TORONTO, June 10, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable ...
MORRISVILLE, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results